Improving Therapeutic Vaccination Against Hepatitis B-Insights from Preclinical Models of Immune Therapy Against Persistent Hepatitis B Virus Infection

Overview

Journal Vaccines (Basel)

Date 2021 Nov 27

PMID 34835264

Citations 5

Authors

Percy A Knolle

Li-Rung Huang

Anna Kosinska

Dirk Wohlleber

Ulrike Protzer

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis B affects more than 250 million individuals worldwide, putting them at risk of developing liver cirrhosis and liver cancer. While antiviral immune responses are key to eliminating hepatitis B virus (HBV) infections, insufficient antiviral immunity characterized by failure to eliminate HBV-infected hepatocytes is associated with chronic hepatitis B. Prophylactic vaccination against hepatitis B successfully established protective immunity against infection with the hepatitis B virus and has been instrumental in controlling hepatitis B. However, prophylactic vaccination schemes have not been successful in mounting protective immunity to eliminate HBV infections in patients with chronic hepatitis B. Here, we discuss the current knowledge on the development and efficacy of therapeutic vaccination strategies against chronic hepatitis B with particular emphasis on the pathogenetic understanding of dysfunctional anti-viral immunity. We explore the development of additional immune stimulation measures within tissues, in particular activation of immunogenic myeloid cell populations, and their use for combination with therapeutic vaccination strategies to improve the efficacy of therapeutic vaccination against chronic hepatitis B.

Citing Articles

Design of multi-epitope-based therapeutic vaccine candidates from HBc and HBx proteins of hepatitis B virus using reverse vaccinology and immunoinformatics approaches.

Naully P, Tan M, Nugrahapraja H, Artarini A, Aditama R, Giri-Rachman E PLoS One. 2024; 19(12):e0313269.

PMID: 39642099 PMC: 11623480. DOI: 10.1371/journal.pone.0313269.

Mouse Models for Chronic Hepatitis B: Old Challenges, Novel Approaches.

Broeckhoven E, Dallmeier K Cell Mol Gastroenterol Hepatol. 2024; 19(1):101421.

PMID: 39488331 PMC: 11701997. DOI: 10.1016/j.jcmgh.2024.101421.

mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model.

De Pooter D, Pierson W, Pourshahian S, Dockx K, De Clerck B, Najera I Vaccines (Basel). 2024; 12(3).

PMID: 38543871 PMC: 10976109. DOI: 10.3390/vaccines12030237.

HBV Vaccines: Advances and Development.

Mahmood F, Xu R, Awan M, Song Y, Han Q, Xia X Vaccines (Basel). 2023; 11(12).

PMID: 38140265 PMC: 10747071. DOI: 10.3390/vaccines11121862.

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies.

Piermatteo L, DAnna S, Bertoli A, Bellocchi M, Carioti L, Fabeni L Emerg Microbes Infect. 2023; 12(1):2219347.

PMID: 37288750 PMC: 10251786. DOI: 10.1080/22221751.2023.2219347.

References

Zhu D, Liu L, Yang D, Fu S, Bian Y, Sun Z . Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. J Immunol. 2016; 196(7):3079-87. PMC: 4824405. DOI: 10.4049/jimmunol.1502061. View

. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020; 73(5):1170-1218. DOI: 10.1016/j.jhep.2020.08.018. View

Pallett L, Gill U, Quaglia A, Sinclair L, Jover-Cobos M, Schurich A . Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med. 2015; 21(6):591-600. PMC: 4458139. DOI: 10.1038/nm.3856. View

Kurts C, Robinson B, Knolle P . Cross-priming in health and disease. Nat Rev Immunol. 2010; 10(6):403-14. DOI: 10.1038/nri2780. View

Guidotti L, Isogawa M, Chisari F . Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol. 2015; 36:61-6. PMC: 4593767. DOI: 10.1016/j.coi.2015.06.016. View

Lucifora J, Protzer U . Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. J Hepatol. 2016; 64(1 Suppl):S41-S48. DOI: 10.1016/j.jhep.2016.02.009. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Ma Z, Zhang E, Yang D, Lu M . Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol. 2014; 12(3):273-82. PMC: 4654312. DOI: 10.1038/cmi.2014.112. View

Iannacone M, Guidotti L . Mouse Models of Hepatitis B Virus Pathogenesis. Cold Spring Harb Perspect Med. 2015; 5(11). PMC: 4632861. DOI: 10.1101/cshperspect.a021477. View

10.

Pulendran B, Arunachalam P, OHagan D . Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6):454-475. PMC: 8023785. DOI: 10.1038/s41573-021-00163-y. View

11.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

12.

Boni C, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D . HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. Int J Mol Sci. 2019; 20(11). PMC: 6600394. DOI: 10.3390/ijms20112754. View

13.

Baudi I, Kawashima K, Isogawa M . HBV-Specific CD8+ T-Cell Tolerance in the Liver. Front Immunol. 2021; 12:721975. PMC: 8378532. DOI: 10.3389/fimmu.2021.721975. View

14.

MacLachlan J, Cowie B . Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015; 5(5):a021410. PMC: 4448582. DOI: 10.1101/cshperspect.a021410. View

15.

Wei L, Ploss A . Mechanism of Hepatitis B Virus cccDNA Formation. Viruses. 2021; 13(8). PMC: 8402782. DOI: 10.3390/v13081463. View

16.

Kosinska A, Bauer T, Protzer U . Therapeutic vaccination for chronic hepatitis B. Curr Opin Virol. 2017; 23:75-81. DOI: 10.1016/j.coviro.2017.03.011. View

17.

Gill U, McCarthy N . CD4 T cells in hepatitis B virus: "You don't have to be cytotoxic to work here and help". J Hepatol. 2019; 72(1):9-11. DOI: 10.1016/j.jhep.2019.10.008. View

18.

Fumagalli V, Di Lucia P, Venzin V, Bono E, Jordan R, Frey C . Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. J Exp Med. 2020; 217(11). PMC: 7596822. DOI: 10.1084/jem.20200298. View

19.

Manske K, Kallin N, Konig V, Schneider A, Kurz S, Bosch M . Outcome of Antiviral Immunity in the Liver Is Shaped by the Level of Antigen Expressed in Infected Hepatocytes. Hepatology. 2018; 68(6):2089-2105. PMC: 6585666. DOI: 10.1002/hep.30080. View

20.

Tsounis E, Tourkochristou E, Mouzaki A, Triantos C . Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol. 2021; 27(21):2727-2757. PMC: 8173382. DOI: 10.3748/wjg.v27.i21.2727. View